HSA | FSA CARDS ARE NOW ACCEPTED

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Hers or its parent company. No affiliate links or compensation are involved.

Hers and Noom are two of many telehealth programs in the GLP-1 / weight management space. This editorial comparison covers how each program is structured, what they offer, pricing considerations, and the genetic variable neither brand addresses. As of April 2026, the telehealth GLP-1 market includes dozens of options — this piece focuses on the two named in this query.

What Hers is

Hers (Hims & Hers Health) operates as subscription telehealth. Programs in this model typically include virtual clinical evaluation, provider-issued prescriptions, and either brand-name FDA-approved GLP-1 dispensing or compounded semaglutide/tirzepatide via licensed compounding pharmacy pathways. See Hers's official website for current program details.

What Noom is

Noom (Noom, Inc.) operates as app-based subscription with medication add-on. Program structures, medication options, and pricing vary — consult Noom's official website for current details as of the date you read this.

Mechanism and medication approach

Both Hers and Noom operate in the GLP-1 receptor agonist pathway space. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide) modulate appetite regulation, satiety signaling, and gastric emptying. Pharmacological mechanism is identical across any legitimate GLP-1 program — what varies is the business model, the dispensing pathway (brand-name vs compounded), provider oversight, and pricing.

Pricing and access

Pricing for GLP-1 telehealth programs varies widely across the market as of April 2026 — typical monthly totals span approximately $200–$700+ including program fees, medication, and compounded-pharmacy dispensing where applicable. Specific pricing for Hers and Noom is published on each brand's own website. Rather than cite possibly-stale numbers here, verify current pricing directly via each brand's pricing page before any purchase decision.

What the research shows on GLP-1 receptor agonists

The underlying compound class — GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide) — has extensive clinical trial evidence. Key programs: STEP (semaglutide for weight management, NEJM 2021); SURMOUNT (tirzepatide for weight management, NEJM 2022); SURMOUNT-OSA (tirzepatide for obstructive sleep apnea, NEJM 2024). Effect sizes vary by compound, dose, and population. A telehealth program's mechanism is driven by the compound, not by the brand offering it.

What's missing — the genetic variable no telehealth program addresses

Neither program addresses the upstream genetic architecture that shapes every GLP-1 response. Variants in FTO (the fat-mass and obesity-associated gene), GLP1R (the GLP-1 receptor gene — the biological target of every GLP-1 compound), MC4R (a melanocortin receptor central to satiety and energy balance), and TCF7L2 (a transcription factor linked to glucose homeostasis and GLP-1 secretion) map the baseline metabolic terrain on which any GLP-1 compound operates. These variants are pathway-level. They do not predict response to any specific compound, but they do describe the biology a clinician is prescribing into — context that a telehealth prescription alone does not capture.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols — available as Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral. What sets the PlexusDx approach apart is the upstream genetic context. Before starting any GLP-1 pathway protocol, the Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, and 150+ genetic insights — including variants in FTO, GLP1R, MC4R, and TCF7L2 that shape your baseline GLP-1, appetite-regulation, and energy-balance biology. Knowing that genetic profile alongside the protocol itself is the test before you invest approach — turning guesswork into an informed conversation with your healthcare provider.

Not affiliated: PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed in this article.

Related reading on PlexusDx: GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone, What Is GLP 1.

Disclaimer: This article is educational. PlexusDx is not affiliated with Hers and has no commercial relationship with the companies reviewed. PlexusDx offers semaglutide and tirzepatide through its own Weight Management Protocols — this review compares approaches in the GLP-1 telehealth space. The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways — it does not predict response to any specific medication. Consult a qualified healthcare provider before beginning any peptide protocol.

Compare the PlexusDx approach: see the Weight Management Protocols — semaglutide and tirzepatide with the genetic context most telehealth programs don't offer. Or start upstream: take the Precision Peptide Genetic Test to understand your GLP-1 pathway first.

Frequently Asked Questions

Is Hers better than Noom?

Neither Hers nor Noom is objectively "better" — both operate in the GLP-1 telehealth space with similar program structures. What varies is the specific medication options, pricing tiers, and provider model. Individual fit depends on cost, coverage, and program mechanics. Review each brand's own details.

How do Hers and Noom differ on medication?

Both Hers and Noom can prescribe GLP-1 receptor agonists through telehealth. Differences fall in dispensing pathway (FDA-approved brand vs compounded), subscription structure, and provider type. Neither program determines the underlying pharmacology, which is driven by the compound itself rather than the telehealth platform delivering it.

Does genetic testing predict response at Hers or Noom?

No. The Precision Peptide Genetic Test does not predict response to any specific compound or telehealth program. It analyzes pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that shape baseline GLP-1 biology — the upstream context that applies across every GLP-1 program regardless of brand.

How does PlexusDx compare to Hers and Noom?

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, paired with upstream genetic context via the Precision Peptide Genetic Test. The differentiator is pathway-level genetic insight that maps FTO, GLP1R, and MC4R variants — context not offered at Hers, Noom, or most other GLP-1 telehealth programs.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education